Bucillamine

Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA) [1][2].

Product Specifications

CAS Number

[65002-17-7]

Product Name Alternative

SA96; Thiobutarit

UNSPSC

12352211

Hazard Statement

H302-H318-H410

Target

VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/bucillamine.html

Purity

98.87

Solubility

H2O : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

SC[C@@H](C(O)=O)NC(C(C)(S)C)=O

Molecular Formula

C7H13NO3S2

Molecular Weight

223.31

Precautions

P264-P270-P273-P280-P305+P351+P338-P330-P391-P501

References & Citations

[1]Amersi F, et al. Bucillamine, a thiol antioxidant, prevents transplantation-associated reperfusion injury. Proc Natl Acad Sci U S A. 2002 Jun 25;99 (13) :8915-20.|[2]Yanagi Y, et al. Subconjunctival administration of bucillamine suppresses choroidal neovascularization in rat. Invest Ophthalmol Vis Sci. 2002 Nov;43 (11) :3495-9.